IRCT20221102056378N1
Recruiting
Phase 3
Evaluating the effects of empagliflozin in preventing myocardial damage in patients undergoing percutaneous coronary intervention: a double-blind randomized clinical trial
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Cardiovascular disease.
- Sponsor
- Tabriz University of Medical Sciences
- Enrollment
- 90
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 18\-80 years
- •Ischemic heart diseases patients
- •candidate for angioplasty and stentstent insertion
- •Filling of consent form
Exclusion Criteria
- •History of infarction
- •History of open heart surgery in the last 3 months
- •Renal dysfunction
- •Failed History of Coronary Angioplasty
- •cardiogenic shock
- •Liver failure
- •Autoimmune disease
- •History of serious allergy to empagliflozin
- •Inability in filling and understanding of the consent form
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after heart surgeryAtrial fibrillation after heart surgery.Paroxysmal atrial fibrillationIRCT20120520009801N9Mashhad University of Medical Sciences160
Not Yet Recruiting
Phase 3
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
Completed
Phase 1
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30
Not Yet Recruiting
Phase 3
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology
Completed
Phase 3
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138